Home Cell Cycle Wee1

Wee1

Wee1 Products

  • All (5)
  • Wee1 Inhibitors (5)
  • New Wee1 Products
Catalog No. Product Name Information Product Use Citations Product Validations
S1525 Adavosertib (MK-1775) Adavosertib (MK-1775, AZD1775) is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM in a cell-free assay; hinders G2 DNA damage checkpoint. Phase 2.
Science, 2024, 384(6700):eadk0775
Nat Biomed Eng, 2024, 10.1038/s41551-024-01273-9
Nat Commun, 2024, 15(1):2089
S8148 PD0166285 PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations (IC50=24 nM for Wee1 and 72 nM for Myt1). PD0166285 is also a novel G2 checkpoint abrogator. PD0166285 induces apoptosis.
Nat Commun, 2024, 15(1):2089
medRxiv, 2024, 2023.05.17.23290140
Nat Commun, 2023, 14(1):6088
S9778 Debio 0123 WEE1-IN-5 (Debio 0123) is a potent Wee1 inhibitor that inhibits phospho-CDC2 and abrogates the G2 check point.
medRxiv, 2024, 2023.05.17.23290140
E1000 Azenosertib (Zn-C3) Azenosertib (Zn-C3) is an oral active, highly effective and selective Wee1 inhibitor with IC50 of 3.9 nM, which can be used in cancer research.
medRxiv, 2024, 2023.05.17.23290140
E4737New Potrasertib Potrasertib (IMP7068, WEE1-IN-10) is a potent and selective inhibitor of WEE1 Kinase. It displays antitumor activity and is well-tolerated in patients with advanced solid tumors.
S1525 Adavosertib (MK-1775) Adavosertib (MK-1775, AZD1775) is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM in a cell-free assay; hinders G2 DNA damage checkpoint. Phase 2.
Science, 2024, 384(6700):eadk0775
Nat Biomed Eng, 2024, 10.1038/s41551-024-01273-9
Nat Commun, 2024, 15(1):2089
S8148 PD0166285 PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations (IC50=24 nM for Wee1 and 72 nM for Myt1). PD0166285 is also a novel G2 checkpoint abrogator. PD0166285 induces apoptosis.
Nat Commun, 2024, 15(1):2089
medRxiv, 2024, 2023.05.17.23290140
Nat Commun, 2023, 14(1):6088
S9778 Debio 0123 WEE1-IN-5 (Debio 0123) is a potent Wee1 inhibitor that inhibits phospho-CDC2 and abrogates the G2 check point.
medRxiv, 2024, 2023.05.17.23290140
E1000 Azenosertib (Zn-C3) Azenosertib (Zn-C3) is an oral active, highly effective and selective Wee1 inhibitor with IC50 of 3.9 nM, which can be used in cancer research.
medRxiv, 2024, 2023.05.17.23290140
E4737New Potrasertib Potrasertib (IMP7068, WEE1-IN-10) is a potent and selective inhibitor of WEE1 Kinase. It displays antitumor activity and is well-tolerated in patients with advanced solid tumors.
E4737New Potrasertib Potrasertib (IMP7068, WEE1-IN-10) is a potent and selective inhibitor of WEE1 Kinase. It displays antitumor activity and is well-tolerated in patients with advanced solid tumors.

Choose Selective Wee1 Inhibitors

Wee1Signaling Pathway

Wee1信号通路图
Tags: Wee1 inhibitor|Wee1 agonist|Wee1 activator|Wee1 inducer|Wee1 antagonist|Wee1 signaling pathway|Wee1 assay kit